Engineered immune cells take on tough lymphoma
NCT ID NCT07473167
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called TC011, which uses a patient's own immune cells engineered to find and attack lymphoma cells. It is for adults with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The trial will check safety and how well the therapy works in 98 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TC011 (a type of CAR-T cell therapy that targets CD19 on cancer cells)
- What this could lead to
- If successful, this could offer a new treatment option for people with hard-to-treat large B-cell lymphoma that has not responded to standard chemotherapy.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with only 98 participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome and nervous system problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, Seoul, 03080, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo keep aggressive lymphoma at bay?
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- Can a single shot build a cancer army inside the body?
- Can a smart immune cell with a kill switch beat tough lymphomas?
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- New drug combo aims to boost lymphoma treatment